INTRODUCTION
Infants treated with extracorporeal membrane oxygenation (ECMO) are at risk for cerebral injury. The mechanisms of such brain injury are complex, and include hypoxic-ischemic damage that occurs prior to ECMO, as well as abnormalities in cerebral blood flow and metabolic activity that may occur during this therapy. 1 -3 Structural abnormalities of the brain are readily identified by computerized tomography (CT) or magnetic resonance imaging (MRI), for which correlations between imaging abnormalities and later adverse neurodevelopmental sequelae in infants have been described. 4 -8 However, because of intensive care requirements, and the technical difficulty in transporting infants on ECMO, the CT or MRI must be deferred until after the completion of ECMO therapy, delaying the identification of serious brain injury.
Most ECMO centers perform serial head ultrasound (HUS) studies at the bedside before or during ECMO to assess the development or progression of intraventricular hemorrhage (IVH), a relative contraindication for ECMO therapy that requires systemic heparinization. HUS is a useful imaging test for the detection of major, centrally located bleeding, but it is not as sensitive as CT or MRI for identifying other clinically significant brain parenchymal lesions, such as ischemia or infarction. 9 Electroencephalography (EEG) is also a portable study of the brain that can be performed at the bedside of the critically ill infant, and the utility of the EEG during ECMO has more recently been described. 10 -14 Abnormalities on the EEG reflect both the severity and acuteness of brain dysfunction, regardless of the underlying pathology. 15, 16 Nevertheless, specific EEG abnormalities may be indicative of specific types of brain injury, 17 and markedly abnormal recordings during ECMO therapy can be predictive of a poor prognosis (mortality and central nervous system morbidity). 13, 14 Because adverse neurologic and cognitive outcomes are approximately twice as common in ECMO-treated infants with significant CT or MRI neuroimaging abnormalities when compared with those without such abnormalities, 4 -6 earlier knowledge of CT or MRI results would be clinically useful. Because both HUS and EEG can be used at the bedside as indicators of acute brain injury during ECMO therapy, we hypothesized that a combination of these studies could be used during the ECMO course as predictors for brain abnormalities to be identified subsequently on post-ECMO CT or MRI. The purpose of this study was to determine if the combination of EEG and HUS during ECMO would be more highly Definitive neuroimaging of the brain using computerized tomography ( CT ) or magnetic resonance imaging ( MRI ) in extracorporeal membrane oxygenation ( ECMO ) -treated infants must be delayed until after this therapy is completed. Bedside head ultrasound ( HUS ) and electroencephalography ( EEG ) studies during ECMO, if highly correlated with later definitive neuroimaging, might be used to affect the acute clinical care and early parental counseling of infants with severe cardiorespiratory failure. One hundred and sixty ECMO -treated patients had both bedside EEG and HUS studies performed during ECMO, as well as a later CT or MRI study prior to hospital discharge. There was a significant difference in CT or MRI findings among patients having normal studies on both the HUS and EEG, compared to those having an abnormality on either the HUS or the EEG, and compared to those having abnormalities on both studies. In ECMO -treated infants, the combination of a normal bedside HUS and an EEG without marked abnormalities is highly predictive of normal post -ECMO CT and MRI neuroimaging studies. 
Original Article
correlated than either study alone with subsequent brain CT or MRI results.
METHODS
Infants referred to the newborn intensive care unit at Thomas Jefferson University Hospital for ECMO therapy, as well as those inborn infants with refractory respiratory failure, were prospectively enrolled into a comprehensive neurodevelopmental outcomes research protocol after IRB approved informed parental consent. The medical records of all 248 patients treated with ECMO at our institution between January 1985 and December 1993 were retrospectively reviewed. Records were limited through 1993 because our database represented complete studies with up to 4 years followup, partially supported by research grants. Patients were eligible for inclusion in this study if they have had at least one EEG and HUS performed during ECMO therapy, as well as a CT or MRI study after discontinuation of ECMO, but prior to hospital discharge or transfer. One hundred and sixty patients met criteria for entry into this study. Excluded were patients without CT or MRI examinations (N=70), patients without an EEG during ECMO (N=11), and patients who died prior to post-ECMO neuroimaging with CT or MRI (N=7). All patients met institutional criteria for ECMO due to severe respiratory failure. Standard venoarterial (VA) ECMO was performed in 140 patients, venovenous (VV) ECMO in 17 patients, and venovenous converting to venoarterial ECMO (VV!VA) in 3 patients. Before the initiation of ECMO, all patients underwent a screening HUS examination (clinical standard of care). Subsequently, a HUS study was performed daily during ECMO therapy according to protocol. These studies were performed with either a Toshiba 140 (Toshiba Medical Systems, Tostin, CA) or an Acoustic Imaging 5200 (Acoustic Imaging, Phoenix, AZ) machine equipped with 5 and 7.5 MHz sector transducers. Multiple images were obtained through the anterior fontanelle in both the coronal and sagittal planes. All HUS studies were interpreted by board-certified radiologists with expertise in ultrasound interpretation, and without knowledge of the EEG and CT or MRI findings. The presence and severity of IVH was noted, and graded on a scale of 1 to 4 according to Papile et al. 18 The presence and severity of increased periventricular echogenicity (PVE) were also determined. A ''normal'' HUS was defined as one with no or only grade 1 IVH, and no or only mildly increased PVE because grade 1 IVH and mild PVE have not been correlated with adverse outcomes previously. 3, 5, 9 The highest grade or level of abnormality on HUS was recorded for each patient.
Bedside EEG studies were performed at least once during ECMO using a modification of the International 10/20 System for electrode placement. A minimum of 30 minutes of technically acceptable tracing was required. A detailed description of the EEG technique used at our institution has been published previously. 11 The EEG recordings were classified based on the criteria of Tharp and Laboyrie. 19 EEGs were reported as normal, mildly abnormal, moderately abnormal, or markedly abnormal. Marked abnormalities included the following patterns: electrographic seizures, isoelectric or burst suppression, focal or generalized suppression, and focal or generalized slowing. The marked EEG abnormalities burst suppression and seizures have been reported to predict mortality or severe neurologic impairment previously, 14, 20 and were recorded as significant events for this study. Normal, mildly, and moderately abnormal EEGs were not coded as significantly abnormal. All EEGs were interpreted by one of the authors (L.J.S.) who was unaware of the patient's condition or the neuroimaging results. For patients having more than one EEG before or during ECMO, the most severe grade of EEG abnormality was used for data analysis.
CT and MRI examinations were performed on all study subjects after the completion of ECMO and before hospital discharge or transfer. The CT scans were performed on a GE High-Speed scanner (GE Medical Systems, Milwaukee, WI) or GE 9800 Quick Highlight scanner without contrast enhancement. Magnetic resonance images were obtained with a GE Signa 1.5-T magnet without contrast enhancement. Board-certified neuroradiologists without knowledge of the HUS and EEG findings or patient condition interpreted all CT and MRI studies. CT and MRI studies were considered abnormal if there was one or more of the following findings: cerebral atrophy, infarction, periventricular leukomalacia, or intraparenchymal hemorrhage. 3 Other specific CT or MRI abnormalities, such as congenital malformations and possible TORCH infections, were not included as abnormal for purposes of this study. The CT or MRI results were used as our ''gold standard'' for identifying structural brain injury.
All demographic data were collected by review of the medical record for each patient. Group data were compared with -squared analysis and unpaired Student's t-tests. Discrimination analysis for determining positive and negative predictive values, and for sensitivity and specificity was also performed.
RESULTS
Of the 160 patients in this study, 157 were treated in the neonatal period, and 3 were older infants (age at ECMO initiation was 40, 55, and 134 days, respectively). Patient demographics are described in Table 1 . Gestational age and birth weights were statistically lower in patients with normal CT or MRI studies, but this finding was not felt to be clinically significant. None of the other characteristics differed significantly between those with and without CT or MRI abnormalities.
Overall, 120 patients (75%) had normal and 40 patients (25%) had abnormal CT or MRI studies (Table 2 ). Mean time from ECMO initiation to performance of the CT or MRI was 18 days (range 5 to 75 days), and did not differ between those with normal studies compared with those with abnormal studies. There was no tendency toward lateralization of CT/MRI abnormalities, nor a predominant side for infarctions or hemorrhages. Although the HUS was significantly related to CT/MRI results (p<.001, Table 2 ), the predictive value of HUS for detecting subsequent CT or MRI structural Gannon et al.
Abnormal CT or MRI After ECMO abnormalities was only 56%, and for predicting a normal CT or MRI was 81%. In contrast, the EEG findings alone in patients with and without CT/MRI abnormalities showed no significant difference with respect to the incidence of marked EEG abnormalities. Of the 40 patients with an abnormal CT or MRI, 26 (65%) had at least one significant abnormality on EEG. Their abnormalities included: seven electrographic seizures, nine burst suppression, six generalized suppression, five focal suppression, and five focal slowing. Fifty-two patients (43%) had markedly abnormal EEG studies in the 120 patients with later normal neuroimaging with CT or MRI. These included: 2 electrographic seizures, 21 burst suppression, 9 generalized suppression, 4 focal suppression, 5 generalized slowing, and 15 focal slowing. Some patients had more than one abnormality present on their worst EEG recording. The EEG alone was more sensitive (65%) and less specific (57%) than HUS alone in correlating with later CT or MRI results.
When considered together, EEG and HUS findings differed significantly between patients with and without abnormal CT/MRI studies, as shown in Table 3 : 69% of patients with abnormalities on both HUS and EEG had severely abnormal findings revealed subsequently on post-ECMO CT or MRI studies (positive predictive value, p<.001). When both HUS and EEG were normal during ECMO, 88% of patients had a normal CT or MRI (negative predictive value). In patients having either an abnormal HUS or an abnormal EEG (''single abnormality''), 71% still had a normal CT or MRI. In patients with normal HUS studies throughout their ECMO course (N=133), EEG evidence of seizures differed significantly between patients with and without abnormal CT/MRI findings. Electrographic seizures occurred in 5 of 25 patients (20%) with an abnormal CT/MRI, but in only 2 of 108 patients (2%) with a normal CT or MRI (p<.005). In patients with abnormal HUS during ECMO (N=27), electrographic seizures were found in 3 of 15 patients with an abnormal CT or MRI, and did not occur in the 12 patients with a normal CT or MRI (p=NS). None of the other marked EEG abnormalities assessed in this study differed significantly when similarly analyzed.
Of the nine patients whose only abnormality on HUS was significant PVE, four were found to have infarcts or PVL by later CT or MRI, three of whom exhibited seizures or burst suppression on EEG. Of the remaining five patients with normal CT/MRI studies, none exhibited seizures or burst suppression on EEG.
When we limited the CT/MRI abnormalities of interest to intraparenchymal hemorrhages and hemorrhagic infarctions (N=18), lesions that might be cause for termination of ECMO support because of systemic heparinization, HUS alone detected only 8 (44%). For the 10 remaining patients with a normal HUS, the EEG demonstrated seizures or lateralizing abnormalities in eight (p<.01).
DISCUSSION
In the present study, we found the EEG to be a useful adjunct to the standard HUS for predicting later definitive neuroimaging results by CT or MRI. At the time of ECMO initiation, all babies were critically ill, and patient characteristics of those whose later CT or MRI images were normal did not differ from those with abnormal images. Therefore, it is difficult to predict early on during the acute phase of illness which infants will go on to develop significant brain injury. We found, moreover, that an EEG without marked abnormalities improved the predictive value for a normal post-ECMO CT or MRI when paired with a normal HUS during ECMO. In particular, the presence of seizures with an abnormal HUS study while on ECMO was an ominous sign.
The neurodevelopmental outcome of ECMO survivors is of considerable importance because large numbers of children are being treated with this therapy. Parents frequently ask clinicians to prognosticate regarding long-term outlook early in the course of ECMO. The most consistent predictor for adverse neurologic and cognitive outcomes is the presence of major neuroimaging abnormalities on CT or MRI following therapy with ECMO. 5,7,8,10 -14,22 -25 Kornhauser et al. 22 from our institution reported lower BSID (at 23 months) and MSEL (at 44 months) scores in ECMO-treated patients with significant abnormalities on CT or MRI prior to discharge.
Similarly, Glass et al. 4 noted that intracranial abnormalities demonstrated on CT scan were associated with poor outcome at 1 year of age. Lago et al. 7 noted that enlarged cerebrospinal fluid spaces, not solely widened intrahemispheric fissures (designated in the present study as ''atrophy''), detected on MRI post-ECMO were significantly associated with lower Bayley scores for both mental and psychomotor evaluations at 6 and 12 months. The occurrence of adverse neurodevelopmental outcome at 12 to 30 months was associated with moderate or severe neuroimaging abnormalities in ECMO-eligible survivors in a report by Vaucher et al. 8 An overall incidence of 25% with severe CT/MRI brain abnormalities in our population is consistent with that found by Lazar et al. 23 and Wiznitzer et al. 24 The detection of peripheral supratentorial and posterior fossa lesions, and differentiating between infarcted and hemorrhagic lesions, comprise limitations of cranial sonography. 9 Taylor et al. 9 detected 26 of 43 intracranial abnormalities (60%) with cranial sonography, whereas Wiznitzer et al. 24 found HUS to have only a 25% sensitivity in detecting significant CNS lesions identified subsequently on MRI. In our study, HUS predicted only 15 of 40 lesions (38%) noted on CT or MRI subsequently. The value of HUS alone for predicting subsequently normal CT or MRI findings is higher than its value in predicting abnormalities.
EEG abnormalities have been reported to occur in a majority of infants before and during ECMO. 11, 12 These abnormalities are often nonspecific and may be associated with a variety of brain disorders. The degree and duration of background abnormality, particularly isoelectric, burst suppression pattern, and electrographic seizures, have been correlated with subsequent adverse neurologic sequelae and poor neurodevelopmental outcome. 10 -12,15,26 Other investigators have found that particular cerebral lesions, such as PVL, infarction, and diffuse neuronal necrosis, can be heralded by particular abnormalities on EEG. Scher et al. 27 and Scher, 28 in a group of 30 term infants with seizures, found structural lesions in 86%, with 23 of 26 lesions being cerebral infarctions. In the present study, we did not assess EEG recordings over time, as many of our ECMO patients, particularly early in our ECMO experience, had only a single EEG on ECMO. However, a recent publication from our institution substantiates the prognostic value of serial EEGs.
14 Similar to other reports, 11 -14 we found the EEG to be at least moderately abnormal in nearly half of our patients treated with ECMO. Although the sensitivity of the EEG was somewhat better than the HUS alone in predicting an abnormal CT or MRI scan, the specificity was lower for predicting normal imaging outcomes.
Combining the EEG and the HUS results in patients treated with ECMO improved both the positive and negative predictive value for subsequent CT or MRI imaging results. Eighty-eight percent of patients with normal EEG and HUS studies subsequently had normal CT or MRI scans. Conversely, nearly 70% of patients with abnormalities on both the EEG and HUS during ECMO was found to have significant CT or MRI scan abnormalities.
Although there is no substitute for definitive CT or MRI neuroimaging and appropriate neurodevelopmental follow-up after ECMO therapy, we suggest that bedside HUS combined with EEG studies performed during the acute hospital course provide early information useful for counseling of parents and assessing prognosis.
